Please assess the completion status of the following clinical trial:

Trial Title: GFM-Acadesine: A Phase I-II Trial of Acadesine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Myelodysplastic syndrome including the following WHO categories: refractory anemia with excess blasts (RAEB), non-proliferative chronic myelomonocytic leukemia (CMML) (leukocytes \< 13 G/L but \> 10% marrow blasts), WHO- AML with 20-30% marrow blasts (RAEB-T according to the FAB classification)~* Prior treatment with Azacitidine or Decitabine for at least 6 courses without response (including CR, PR, marrow CR and stable disease with hematological improvement) or relapse after a response~* IPSS score \>1 (IPSS: Int-2 or High);~* Age ≥ 18 years;~* Normal liver function tests, defined by total bilirubin and transaminases less than 1.5 time the upper limit of normal;~* Normal renal function, defined by creatinine less than 1.5 time the upper limit of normal, creatinine clearance ≥ 50 mL/min.~* Patient ineligible for allogeneic hematopoietic stem cell transplantation;~* Written informed consent;~* Patient must understand and voluntarily sign consent form;~* Patient must be able to adhere to the visit schedule as outlined in the study and follow protocol requirements;~* ECOG performance status between 0-2 at the time of screening;~* Women of childbearing potential must:~Agree to use effective contraception without interruption throughout the study and for a further 1 month after the end of treatment;~* Men must:~Agree to not conceive during the treatment and to use effective contraception during the treatment period (including periods of dose reduction or temporary suspension) and for a further 1 month after the end of treatment if their partner is of childbearing potential.~Exclusion Criteria:~* Severe infection or any other uncontrolled severe condition~* Significant cardiac disease - NYHA Class III or IV or having suffered a myocardial infarction in the last 6 months~* Less than 30 days since prior treatment with growth factors (EPO, G-CSF)~* Use of investigational agents within 30 days or any anticancer therapy within 2 weeks before study entry with the exception of hydroxyurea. The patient must have recovered from all acute toxicities from any previous therapy.~* Active cancer, or cancer during the year prior to trial entry other than basal cell carcinoma or carcinoma in situ of the cervix or breast;~* Patient already enrolled in another therapeutic trial of an investigational drug;~* HIV infection or active hepatitis B or C;~* Women who are or could become pregnant or who are currently breastfeeding;~* Any medical or psychiatric contraindication that would prevent the patient from understanding and signing the informed consent form;~* Patient eligible for allotransplantation.~* Known allergy to acadesine or any of its excipients~* No affiliation to an insurance system

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ACADESINE 140mg/kg/d (Type: EXPERIMENTAL): 3 patients will be included at the initial dose of Acadesine 140mg/kg/d
- ACADESINE 210mg/kg/d (Type: EXPERIMENTAL): In absence of toxicity at the dose of 140mg/kg/d. There is a dose escalation of acadesine at the dose of 210mg/kg/d for 3 additionnal patients
- ACADESINE 315mg/kg/d (Type: EXPERIMENTAL): In absence of toxicity at the dose of 210mg/kg/d. There is a dose escalation of acadesine at the dose of 315mg/kg/d for 3 additionnal patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues